Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648957 | 0.98 | CNR2 (0.53) | CNR2EGFRPRKDCKDRERBB2 | |
| Hydrochloric Acid SCHEMBL4910087 | 0.97 | CNR2 (0.52) | CNR2EGFRPRKDCKDRERBB2 | |
| SCHEMBL14006031 | 0.92 | CNR2 (0.51) | CNR2EGFRPRKDCKDR | |
| SCHEMBL4650337 | 0.91 | CNR2 (0.50) | CNR2EGFRPRKDCERBB2CHRNB4 | |
| SCHEMBL14006008 | 0.91 | CNR2 (0.50) | CNR2EGFRPRKDCKDRERBB2 | |
| Hydrochloric Acid SCHEMBL4689672 | 0.90 | CNR2 (0.49) | CNR2EGFRPRKDCKDRERBB2 | |
| SCHEMBL14065242 | 0.87 | PIK3CA (0.43) | CNR2EGFRPRKDCERBB2 | |
| SCHEMBL4649706 | 0.82 | CNR2 (0.61) | CNR2EGFRKDRERBB3 | |
| SCHEMBL14006034 | 0.79 | CNR2 (0.59) | CNR2EGFRPRKDCERBB3 | |
| Hydrochloric Acid SCHEMBL4649162 | 0.78 | CNR2 (0.58) | CNR2EGFRPRKDCERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885EGFR 818/4885PRKDC 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.